Clinical applicability of the evaluation of minimal residual disease in acute leukemia
- 1 January 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 12 (1) , 36-40
- https://doi.org/10.1097/00001622-200001000-00006
Abstract
Modern chemotherapy can place most patients with acute leukemia into remission. Unfortunately, many of these patients will subsequently relapse. The study of minimal residual disease focuses on the detection of patients destined to relapse despite appearing to be in clinical remission. In addition, the research has demonstrated that some patients appear to co-exist with their leukemia for years, and this suggests a need to re-examine what it means to be "cured" of leukemia. We await trials testing the intervention of "molecular relapse." Data appear to be sufficient to launch such trials in diseases such as pediatric acute lymphoblastic leukemia and the t(1 5;1 7) acute myeloid leukemia.Keywords
This publication has 18 references indexed in Scilit:
- A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detectionLeukemia, 1999
- Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probesLeukemia, 1998
- Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic LeukemiaBlood, 1998
- Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia.Journal of Clinical Oncology, 1998
- Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemiaBritish Journal of Haematology, 1998
- Multiplex Reverse Transcription-Polymerase Chain Reaction for Simultaneous Screening of 29 Translocations and Chromosomal Aberrations in Acute LeukemiaBlood, 1998
- Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcomeLeukemia, 1998
- Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemiaThe Lancet, 1998
- Minimal residual disease analysis for the prediction of relapse in children with standard‐risk acute lymphoblastic leukaemiaBritish Journal of Haematology, 1998